Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are delighted to announce the launch of the new Oxford Centre for Neuroinflammation (OCNI), which aims to shed light on the causes of neurodegenerative diseases and uncover new treatment pathways

© John Cairns

Headed by Professor Lars Fugger, the centre will bring together biomedical, analytical and clinical expertise, to investigate the neuroinflammatory mechanisms that underpin a range of neurodegenerative diseases including multiple sclerosis, Parkinson’s and Alzheimer’s. This will allow our researchers to develop new tools for faster diagnosis, more accurate prognosis and new targets for life-changing and life-saving treatments.

We hope that the opening of the OCNI will help accelerate our understanding of neurodegenerative diseases and thus pave the way for novel treatments for patients worldwide - Professor Lars Fugger

In particular, the OCNI will capitalise on recent technological advances, including next generation experimental platforms, genetic microsurgery techniques and single-cell analysis methods, as well as on the on-going ‘big data’ explosion, which is enabling access to genetic, clinical and epidemiological information from hundreds of thousands of patients. By combining cutting-edge scientific approaches with clinically relevant data sets and with direct access to patient samples, the OCNI will be uniquely placed to drive forward medical research, interrogating the neuroinflammatory basis of neurodegenerative diseases.

Funded by the Oak Foundation and private donors the centre will ensure that new findings within the field are translated back to real progress in the clinic. The centre will focus on four major goals:

  1. Understanding how genetic information can be harnessed to help facilitate diagnosis
  2. Investigating the interplay between environmental factors and disease
  3. Establishing how to predicted drug efficacy
  4. Ascertaining whether drugs already tested and approved can be re-purposed for the treatment of neurodegenerative disease.

By addressing these questions, the centre will help to provide life changing therapeutic options to enable patients worldwide to live active and fulfilling lives. 

Find out more 

Similar stories

NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills

Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said.

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Unique study of vascular disease reaches 20th anniversary

The only project of its kind anywhere that studies patients with all types of acute vascular events - including strokes, heart attacks, aneurysms - in order to develop better diagnostic tests and treatments celebrates its 20th anniversary this month.

New funding awarded to study persistent pain in inflammatory arthritis

The £3.9M Wellcome Collaborative Award will be used to identify the drivers of pain in people living with rheumatoid arthritis.

Massive Publicity for Study of Effects of Mild COVID on Smell

Researchers from the University of Oxford have used data from UK Biobank participants to look at changes to the brain on average 4.5 months after mild SARS-CoV-2 infection.